1. Home
  2. AUPH vs BELFA Comparison

AUPH vs BELFA Comparison

Compare AUPH & BELFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • BELFA
  • Stock Information
  • Founded
  • AUPH 1993
  • BELFA 1949
  • Country
  • AUPH Canada
  • BELFA United States
  • Employees
  • AUPH N/A
  • BELFA N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • BELFA
  • Sector
  • AUPH Health Care
  • BELFA
  • Exchange
  • AUPH Nasdaq
  • BELFA Nasdaq
  • Market Cap
  • AUPH 1.6B
  • BELFA 1.6B
  • IPO Year
  • AUPH 1999
  • BELFA N/A
  • Fundamental
  • Price
  • AUPH $12.54
  • BELFA $139.00
  • Analyst Decision
  • AUPH Strong Buy
  • BELFA
  • Analyst Count
  • AUPH 2
  • BELFA 0
  • Target Price
  • AUPH $13.00
  • BELFA N/A
  • AVG Volume (30 Days)
  • AUPH 1.2M
  • BELFA 11.8K
  • Earning Date
  • AUPH 11-10-2025
  • BELFA 10-29-2025
  • Dividend Yield
  • AUPH N/A
  • BELFA 0.17%
  • EPS Growth
  • AUPH N/A
  • BELFA N/A
  • EPS
  • AUPH 0.42
  • BELFA 4.05
  • Revenue
  • AUPH $260,111,000.00
  • BELFA $594,034,000.00
  • Revenue This Year
  • AUPH $17.33
  • BELFA $25.48
  • Revenue Next Year
  • AUPH $14.31
  • BELFA $5.57
  • P/E Ratio
  • AUPH $30.05
  • BELFA $34.19
  • Revenue Growth
  • AUPH 25.59
  • BELFA 6.08
  • 52 Week Low
  • AUPH $6.55
  • BELFA $53.95
  • 52 Week High
  • AUPH $13.54
  • BELFA $141.50
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 60.86
  • BELFA 72.11
  • Support Level
  • AUPH $11.48
  • BELFA $123.58
  • Resistance Level
  • AUPH $12.70
  • BELFA $141.50
  • Average True Range (ATR)
  • AUPH 0.34
  • BELFA 4.49
  • MACD
  • AUPH 0.13
  • BELFA 2.08
  • Stochastic Oscillator
  • AUPH 89.64
  • BELFA 91.58

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About BELFA Bel Fuse Inc.

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

Share on Social Networks: